#radio #podcast #trójka #PR3 📻
Na stronie Polskiego Radia można znaleźć nagrania wielu audycji, ale nie wszystkich. Co innego tu:
http://3.dktr.pl/
Tu jest chyba wszystko od Bożego Narodzenia 2021 UwU
3.dktr.pl Archiwum Trójki, player online

The #Plastic Reduction Project (#PR3 https://www.pr3standards.org ) is seeking public input on a reuse symbol https://docs.google.com/forms/d/e/1FAIpQLSfHuq5HwSbAMIu6IahwXIYyFpim-qTs2ch5pFqdowBhE5gWvg/viewform
According to their website, "PR3 and its global partners are advancing Reuse Standards to support and empower the move away from single-use packaging."
#reuse #singleuse #ConsumerPackaging
PR3 - The Alliance to Advance Reuse

PR3 and its global partners are advancing Reuse Standards to support and empower the move away from single-use packaging.

PR3 Reuse Done Right.

I wonder if inflammatory/immune related pathology in severe covid is similar to #autoimmune #vasculitis diseases.

🐘 Are patients with severe covid disease, also #ANCA #PR3 positive? 🐘

This article 👇🏼not only discusses pathology, but treatment and Rx outcomes of various forms of vasculitis 👉🏼which might have relevance in management of cases of covid where #thrombosis contributes significantly to seriousness of disease

https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-015-0047-z

Thrombosis in vasculitis: from pathogenesis to treatment - Thrombosis Journal

In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected.Inflammation-induced thrombosis is by now considered a feature not only of autoimmune rheumatic diseases, but also of systemic vasculitides such as Behçet’s syndrome, ANCA-associated vasculitis or giant cells arteritis, especially during active disease.These findings have important consequences in terms of management and treatment. Indeed, Behçet’syndrome requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory treatment during active disease could reduce the risk of thrombotic events in early stages.In this review we discuss thrombosis in vasculitides, especially in Behçet’s syndrome, ANCA-associated vasculitis and large-vessel vasculitis, and provide pathogenetic and clinical clues for the different specialists involved in the care of these patients.

BioMed Central